Cover Image
市場調查報告書

克隆氏症診斷及治療的全球市場:成長,趨勢與預測(2017年∼2022年)

Global Crohns Disease Diagnostic and Therapeutic Market Growth, Trends and Forecast (2017 - 2022)

出版商 Mordor Intelligence LLP 商品編碼 391371
出版日期 內容資訊 英文 205 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
克隆氏症診斷及治療的全球市場:成長,趨勢與預測(2017年∼2022年) Global Crohns Disease Diagnostic and Therapeutic Market Growth, Trends and Forecast (2017 - 2022)
出版日期: 2017年01月24日 內容資訊: 英文 205 Pages
簡介

克隆氏症(CD)是一種炎症性腸病(IBD),影響從口腔到肛門的胃腸道的任何部分。由於遺傳易感人群中的環境因素,免疫因素和細菌因素共同造成的。據亞特蘭大CDS估計,每10萬人中約有200人受到影響,發病率為每10萬人每年3.1至14.6人。

本報告提供全球克隆氏症診斷及治療市場調查,整體市場趨勢,各產品、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等,總括性彙整。

目錄

第1章 簡介

  • 調查的成果
  • 市場定義
  • 數量單位
  • 基本貨幣
  • 檢討與預測期間
  • 一般調查的前提條件

第2章 調查方法

  • 簡介
  • 分析方法論
  • 計量預測模式
  • 調查的前提條件

第3章 摘要整理

第4章 關鍵問題

第5章 市場概況及產業的趨勢

  • 目前市場方案
  • 技術概要
  • 治療藥新的發展
  • 投資分析
  • 波特的五力分析
    • 供應商談判力
    • 買主談判力
    • 競爭程度
    • 替代品的威脅
    • 新加入廠商的威脅

第6章 成長要素,阻礙因素,機會及課題分析(DROC)

  • 市場成長要素
    • 這個疾病相關的複數的症狀,必須在個別治療上注意
    • 迅速的診斷的要求
    • 受影響人口隨著時間而增加
  • 市場阻礙因素
    • 市場上沒有可取得的特定治療藥
    • 人們的意識缺乏及與其他腸胃疾病的症狀相似性
    • 缺乏成本效果高的治療方法
  • 市場機會
    • 生物相似藥的出現
    • 抗TNF市售品牌Remicade和Humira等各種有用藥物的專利到期

新參與市場企業的大門

  • 主要課題

第7章 全球克隆氏症診斷及治療市場

  • 回結腸炎
  • 髂骨炎
  • 胃十二指腸的克隆氏症
  • 空腸回腸炎
  • 克隆結腸炎

第8章 全球克隆氏症的診斷及治療市場:各診斷方法

  • 血液檢驗
  • 糞便檢驗
  • 大腸內視鏡檢驗
  • 彈性S狀結腸鏡檢驗
  • 電腦斷層攝影
  • 磁振造影
  • 膠囊內視鏡
  • 雙球囊內視鏡檢驗

第9章 克隆氏症的診斷及治療市場:各治療法

  • 藥、投藥
    • 發炎治療藥
    • 免疫抑劑
    • 止痛藥
  • 手術

第10章 全球克隆氏症診斷及治療市場:各地區(市場佔有率與預測)

  • 北美
    • 簡介
    • 美國
    • 加拿大
    • 其他
  • 歐洲
    • 簡介
    • 法國
    • 英國
    • 德國
    • 西班牙
    • 俄羅斯
    • 義大利
    • 其他
  • 亞太地區
    • 簡介
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 其他
  • 中東、非洲
    • 簡介
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 以色列
    • 其他MEA各國
  • 中南美
    • 簡介
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他

第11章 競爭情形

第12章 主要供應商

  • Abbvie
  • Celgene Corportation
  • Genetech
  • Janssen Biotech Inc.
  • Pfizer Inc.
  • Prometheus Laboratories Inc.
  • Salix Pharmaceuticals Inc.
  • 武田藥品工業
  • Johnnson and Johnnson

第13章 投資機會的分析師預期

第14章 市場未來展望

第8章 附錄

  • 簡稱
  • 參考文獻
  • 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

The therapeutic and diagnostic market for Crohn's disease is accounted to $XX billion for the year 2014 and is anticipated to reach $XX billion at a CAGR of XX% by 2020.Crohn's Disease (CD) is an Inflammatory Bowel's Disease (IBD) that can affect any part of the gastrointestinal tract from mouth to the anus. It is caused by a combination of environmental, immune and bacterial factors in genetically predisposed individuals. It has been estimated by CDS, Atlanta that around 200 per 100,000 population might be affected with an incidence rate of 3.1 to14.6 cases per 100,000 person years.

The therapeutics of treatment of Crohn's disease has been segmented to cope with the various symptoms associated with the disease like anti-inflammatory drugs, immunosuppressive drugs and antipyretics to reduce pain. However, with the introduction of new biotherapies like interleukin inhibitors (IL 12/13) and alpha4beta7 inhibitor, the global drug and therapeutic market for CD will undergo a dynamic change in the near future. With the loss of the patent protection of anti TNF based drugs, the void will be a welcoming platform for many new players. The key players in the therapeutics domain of CD are Takeda's Pharmaceutical Ltd, Abbvie, Johnnson and Johnnson, Celgene Corportation, Genetech, Janssen Biotech Inc, Pfizer Inc., Prometheus Laboratories Inc. and many others.

DRIVERS

The increase in the number of people being affected along with the chronic nature of the disease has made CD one of the prominent health hazards wanting immediate and prominent diagnostic and therapeutic which will be a major contributor of the market drive.

CHALLENGES

With the loss of patent protection of anti TNF based drugs and lack of clarity to distinguish it from other common gastrointestinal ailments, the challenge lies in an effective and efficient therapeutic design.

What the report offers:

1) Market Definition for the specified topic along with identification of key drivers and restraints for the market.

2) Market analysis for the Global Crohn's Disease Market, with region specific assessments and competition analysis on a global and regional scale.

3) Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.

4) Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares

5) Identification and analysis of the Macro and Micro factors that affect the Crohn's Disease Market on both global and regional scale.

6) A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

Table of Contents

1. INTRODUCTION

  • 1.1. Study deliveratives
  • 1.2. Market Definition
  • 1.3. Sizing Units
  • 1.4. Base Currency
  • 1.5. Review and forecasr period years
  • 1.6. General Study Assumptions

2. RESEARCH METHODOLOGY

  • 2.1. Introduction
  • 2.2. Analysis Methodology
  • 2.3. Econometric forecast models

2..4.Research Assumptions

3. EXECUTIVE SUMMARY

4. KEY INFERENCES

5. MARKET OVERVIEW AND INDUSTRY TRENDS

  • 5.1. Current market scenario
  • 5.2. Technology Overview
  • 5.3.New developments in therapeutics
  • 5.4.. Investment analysis
  • 5.5. Porters Five Force Analysis
    • 5.5.1 Bargaining Power of suppliers
    • 5.5.2 Bargaining power of buyers
    • 5.5.3 Degree of competition
    • 5.5.4 Threat of substitution
    • 5.5.5 Threat of new entrants

6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)

  • 6.1. Market Drivers
    • 6.1.1. Multiple symptoms associated with the disease requires individual therapeutic attention.
    • 6.1.2. Demand for prompt diagnosis
    • 6.1.3. Affected population increasing with time
  • 6.2. Market Restraints
    • 6.2.1. No specific treatment or drug available in the market.
    • 6.2.2. Lack of awareness among the people and symptom similarity with other gastrointestinal disease.
    • 6.2.3. Lack of a cost effective form of treatment
  • 6.3 Market Opportunities
    • 6.3.1. Emergence of biosimilars
    • 6.3.2. Patent expiry of various useful drugs, such as Remicade and Humira along with anti TNF marketed brands opens

gates for new players

  • 6.4. Key Challenges

7. Global Crohn's Disease Diagnostic and Therapeutic Market by disease type

  • 7.1. Ileocolitis
  • 7.2. Iletis
  • 7.3. Gastroduodenal crohn's
  • 7.4. Jejunoileitis
  • 7.5. Crohn's colitis

8. Global Crohn's Disease Diagnostic and Therapeutic markey by method of diagnosis

  • 8.1. Blood tests
  • 8.2. Fecal test
  • 8.3. Colonoscopy
  • 8.4. Flexible sigmoidoscopy
  • 8.5. Computerized tomography
  • 8.6. Magnetic resonance imaging
  • 8.7. Capsule endoscopy
  • 8.8. Double ballon endoscopy

9. Global Crohn's Disease Diagnostic and Therapeutic markey by method of treatment

  • 9.1. Drugs and Medication
    • 9.1.1. Medication for inflammation
    • 9.1.2. Medication for immunosupression
    • 9.1.3. Medication for pain relief
  • 9.2. Surgery

10. Global Crohn's Disease Diagnostic and Therapeutic markey by Georaphy - Regional shares and forecast

  • 10.1 North America
    • 10.1.1. Introduction
    • 10.1.2. USA
    • 10.1.3. Canada
    • 10.1.4. Rest of North America
  • 10.2 Europe
    • 10.2.1. Introduction
    • 10.2.2. France
    • 10.2.3. UK
    • 10.2.4. Germany
    • 10.2.5. Spain
    • 10.2.6. Russia
    • 10.2.7. Italy
    • 10.2.8. Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1. Introduction
    • 10.3.2. India
    • 10.3.3. China
    • 10.3.4. Japan
    • 10.3.5. South Korea
    • 10.3.6. Australia
    • 10.3.7. Rest of Asia Pacific
  • 10.4. Middle East and Africa
    • 10.4.1 Introduction
    • 10.4.2. UAE
    • 10.4.3. Saudi Arabia
    • 10.4.4. Israel
    • 10.4.5. Rest of MEA
  • 10.5. Latin America
    • 10.5.1. Introduction
    • 10.5.2. Brazil
    • 10.5.3. Mexico
    • 10.5.4. Argentina
    • 10.5.5. Rest of Latin America

11. COMPETITIVE LANDSCAPE

12.. KEY VENDORS

  • 12.1. Abbvie
  • 12.2. Celgene Corportation
  • 12.3. Genetech
  • 12.4. Janssen Biotech Inc.
  • 12.5. Pfizer Inc.
  • 12.6. Prometheus Laboratories Inc.
  • 12.7. Salix Pharmaceuticals Inc.
  • 12.8. Takeda's Pharmaceutical Ltd.
  • 12.9. Johnnson and Johnnson

13. Analyst outlook for Investment Opportunities

14. Future outlook of the market

8. APPENDIX

  • 8.1 Abbrevations
  • 8.3 Bibliography
  • 8.4 Disclaimer
Back to Top